| Synthesis and cellular bioactivities of novel isoxazole derivatives incorporating an arylpiperazine moiety as anticancer agents B Çalışkan, E Sinoplu, K İbiş, E Akhan Güzelcan, R Çetin Atalay, ... Journal of enzyme inhibition and medicinal chemistry 33 (1), 1352-1361, 2018 | 38 | 2018 |
| The 1, 2, 3-triazole ‘all-in-one’ring system in drug discovery: A good bioisostere, a good pharmacophore, a good linker, and a versatile synthetic tool D Lengerli, K Ibis, Y Nural, E Banoglu Expert opinion on drug discovery 17 (11), 1209-1236, 2022 | 23 | 2022 |
| Synthesis and biological evaluation of novel isoxazole-piperazine hybrids as potential anti-cancer agents with inhibitory effect on liver cancer stem cells K İbiş, E Nalbat, B Çalışkan, DC Kahraman, R Cetin-Atalay, E Banoglu European Journal of Medicinal Chemistry 221, 113489, 2021 | 17 | 2021 |
| Benzoxazolone-5-urea derivatives as human soluble epoxide hydrolase (sEH) inhibitors T Gur Maz, B Koc, PM Jordan, K Ibis, B Çalışkan, O Werz, E Banoglu ACS omega 8 (2), 2445-2454, 2023 | 3 | 2023 |
| Yeni izoksazol türevlerinin sentezi, karaciğer ve meme kanseri hücre hatlarına karşı sitotoksik etkilerinin incelenmesi K İbiş Sağlık Bilimleri Enstitüsü, 2020 | 2 | 2020 |
| Reviving immunogenic cell death upon targeting TACC3 enhances T-DM1 response in HER2-positive breast cancer ME Gedik, O Saatci, N Oberholtzer, M Uner, O Akbulut, M Cetin, M Aras, ... bioRxiv, 2023 | 1 | 2023 |
| Abstract LB275: Reactivation of mitotic arrest upon targeting TACC3 restores immunogenic cell death and T-DM1 response in HER2-positive breast cancer O Saatci, ME Gedik, N Oberholtzer, M Uner, O Akbulut, M Cetin, M Aras, ... Cancer Research 84 (7_Supplement), LB275-LB275, 2024 | | 2024 |
| Targeting TACC3 induces immunogenic cell death and enhances T-DM1 response in HER2-positive breast cancer ME Gedik, O Saatci, N Oberholtzer, M Uner, O Akbulut-Caliskan, M Cetin, ... Cancer Research, 2024 | | 2024 |
| Isoxazole derivatives targeting tacc3 as anticancer agents E Banoglu, B Caliskan, O Sahin, D Lengerli, O Akbulut, LIM Chaemin, ... US Patent App. 17/776,767, 2023 | | 2023 |
| Vicinal Diaryl-Substituted Isoxazole and Pyrazole Derivatives with In Vitro Growth Inhibitory and In Vivo Antitumor Activity S Turanlı, E Nalbat, D Lengerli, K Ibis, S Güntekin Ergün, ... ACS omega 7 (41), 36206-36226, 2022 | | 2022 |
| Synthesis and antiproliferative evaluation of novel isoxazole-piperazine hybrids B Çalışkan, E Sinoplu, K İbiş, E Akhan Güzelcan, R Atalay, E Banoğlu | | 2018 |
| Synthesis, Cytotoxicity and Structure-Activity Relationships of Novel Isoxazole. Derivatives as Anticancer Agents K İbiş, B Çalışkan, E Akhan Güzelcan, E Sinoplu, R Atalay, E Banoğlu | | 2018 |
| Novel isoxazole-piperazine derivatives inhibit the stemness of HCC cells E NALBAT, K İBİŞ, B ÇALIŞKAN, E BANOĞLU, M ATALAY, R ATALAY | | |
| DESIGN, SYNTHESIS AND BIOLOGICAL EVALUATION OF NOVEL IMIDAZOLIDINONE-THIAZOLE AMIDE HYBRIDS AS INHIBITORS OF HUMAN SOLUBLE EPOXIDE HYDROLASE K İbiş, D Lengerli, P Jordan, B Çalışkan, O Werz, E Banoğlu | | |
| KARACİĞER KANSERİ KÖK HÜCRELERİ ÜZERİNDE İNHİBİTÖR ETKİYE SAHİP, POTANSİYEL ANTİKANSER AJANLAR OLARAK YENİ İZOKSAZOL-PİPERAZİN HİBRİTLERİNİN SENTEZİ VE BİYOLOJİK OLARAK … K İbiş, E Nalbat, B Çalışkan, R Atalay, E Banoğlu | | |
| Discovery and Development of Novel Anti-cancer and Anti-inflammatory Compounds: Medicinal Chemistry Challenges E BANOĞLU, B ÇALIŞKAN, Z GÜR MAZ, A OLĞAÇ, K İBİŞ, ... | | |
